An advantaged pathway for effective treatment.
By Nishan K. Shah, Ph.D, Pace Analytical Life Sciences, LLC
It is estimated that by 2050, the number of patients suffering from Alzheimer disease (AD), the most common form of dementia, will quadruple.¹ Therefore, it is of the utmost importance to devote close attention to treat and mitigate its progression. So far, creating new therapeutics for AD has been difficult; however, there are current therapies that have shown some success. Currently, rivastigmine, memantine, and donepezil are all drugs that are used for treating AD. A major obstacle for elderly patients with AD (besides efficacy of the drug) is compliance. Most patients have comorbidities and require taking multiple drugs and may miss a dose.¹ ,³ Along with adverse effects, taking drugs in pill form presents a challenge for such patients.² ,³,⁴,⁵